ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more
ADMA Biologics Inc (ADMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.075x
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has a cash flow conversion efficiency ratio of 0.075x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($35.64 Million) by net assets ($477.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ADMA Biologics Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ADMA Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADMA Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cadence Bancorp
NYSE:CADE
|
0.031x |
|
NH Foods Ltd
F:NI6
|
0.048x |
|
Independent Bank
NASDAQ:INDB
|
0.015x |
|
Soochow Securities Co Ltd
SHG:601555
|
0.336x |
|
Ningbo Orient Wires and Cables Co Ltd
SHG:603606
|
-0.051x |
|
Berner Kantonalbank AG
SW:BEKN
|
0.136x |
|
Petrokent Turizm AS
IS:PKENT
|
0.032x |
|
Zhejiang Jingsheng Mech Electric
SHE:300316
|
-0.003x |
Annual Cash Flow Conversion Efficiency for ADMA Biologics Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of ADMA Biologics Inc from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $477.32 Million | $50.40 Million | 0.106x | -68.95% |
| 2024-12-31 | $349.02 Million | $118.67 Million | 0.340x | +422.41% |
| 2023-12-31 | $135.21 Million | $8.80 Million | 0.065x | +116.62% |
| 2022-12-31 | $151.97 Million | $-59.51 Million | -0.392x | +50.81% |
| 2021-12-31 | $141.17 Million | $-112.37 Million | -0.796x | +31.14% |
| 2020-12-31 | $88.25 Million | $-102.00 Million | -1.156x | +60.27% |
| 2019-12-31 | $26.19 Million | $-76.19 Million | -2.909x | +8.25% |
| 2018-12-31 | $19.77 Million | $-62.68 Million | -3.170x | -243.07% |
| 2017-12-31 | $40.33 Million | $-37.27 Million | -0.924x | -122.55% |
| 2016-12-31 | $-4.46 Million | $-18.27 Million | 4.099x | +121.82% |
| 2015-12-31 | $820.97K | $-15.42 Million | -18.781x | -667.40% |
| 2014-12-31 | $6.01 Million | $-14.70 Million | -2.447x | -384.94% |
| 2013-12-31 | $21.57 Million | $-10.89 Million | -0.505x | +31.11% |
| 2012-12-31 | $9.42 Million | $-6.90 Million | -0.733x | +92.99% |
| 2011-12-31 | $2.77K | $-29.00K | -10.458x | -118.39% |
| 2010-12-31 | $-346.00 | $-19.68K | 56.867x | -- |
| 2009-12-31 | $0.00 | $-24.46 Million | x | -- |
| 2008-12-31 | $0.00 | $-19.00 Million | x | -- |
| 2007-12-31 | $0.00 | $-23.61 Million | x | -- |
| 2006-12-31 | $0.00 | $-23.61 Million | x | -- |